# A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia

> **NCT07692529** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 10 (estimated)

## Conditions studied

- Large Granular Lymphocyte Leukemia
- T-LGL Leukemia

## Interventions

- **DRUG:** zeprumetostat

## Key facts

- **NCT ID:** NCT07692529
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-30
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-02-26
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07692529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07692529, "A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07692529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*